Agere Augments Leadership with Pharmaceutical Manufacturing and Supply Chain Expert
News May 30, 2013
Agere Pharmaceuticals, Inc. announced today that Mr. Michael R. Deperro has joined the company as VP of Operations. The company added cGMP manufacturing capabilities in 2011, and since has expanded facilities to produce Phase I through Phase IIb clinical trials materials for clients.
“Mike brings Agere extensive experience and a strong track record for successfully managing and growing cGMP operations,” commented Marshall Crew, President and CEO of Agere. “He will play a key role as we continue our rapid growth to meet the rigorous expectations of our clients.”
Mr. Deperro has held director and GM-level manufacturing positions at numerous pharmaceutical companies including Alkermes and Taro Pharmaceuticals. He has also been responsible for implementing research and manufacturing infrastructure and operations domestically and abroad for large pharmaceutical and biotechnology companies including Merck and Co. and Novartis. Mr. Deperro’s career focus has been in the areas of drug development, new product launch, and commercialization. His regulatory compliance knowledge of FDA, MHRA, PMDA and ANVISA agencies enhances Agere’s strength in meeting the needs of a growing international client base. Mr. Deperro holds the Bachelor of Science degree in Mechanical Engineering from Notre Dame University, and has earned the Six Sigma Yellow Belt status from the International Society for Six Sigma Certifications.
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
23rd World Congress on Pediatrics, Neonatology & Primary Care
Nov 22 - Nov 23, 2019